Search research articles
Contact Us
Filters
Showing results (391-400 of 411) with videos related to
Page
of 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Georg C Lodde, Philipp Jansen, Inga Möller, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Cancer Discovery
|
November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Eliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
Selina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Lancet (London, England)
|
June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Maximilian Haist, Henner Stege, Friederike Rogall, et al.
Nature Medicine
|
June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Page
of 42
Search research articles
Search
Showing results (391-400 of 411) with videos related to
Sort By:
Page
of 42
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Georg C Lodde, Philipp Jansen, Inga Möller, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Cancer Discovery
|
November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Eliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
Selina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Lancet (London, England)
|
June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Maximilian Haist, Henner Stege, Friederike Rogall, et al.
Nature Medicine
|
June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, et al.
Page
of 42